Want to see JP:4549 full AI Analyst Report?
4549 Stock Chart & Stats
¥2580.00
-¥78.00(-3.07%)
At close: 4:00 PM EDT
¥2580.00
-¥78.00(-3.07%)
Day’s Range― - ―
52-Week Range¥2,021.00 - ¥3,500.00
Previous CloseN/A
Volume357.70K
Average Volume (3M)119.78K
Market Cap
¥75.86B
Enterprise Value¥69.45B
Total Cash (Recent Filing)¥9.89B
Total Debt (Recent Filing)¥5.88B
Price to Earnings (P/E)21.3
Beta0.57
Next Earnings
Jan 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)107.82
Shares Outstanding34,541,440
10 Day Avg. Volume131,650
30 Day Avg. Volume119,776
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.29
Price to Sales (P/S)2.40
P/FCF Ratio-58.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.9
Revenue Forecast (FY)¥43.56B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelRepeated use of diagnostic reagents creates a recurring consumables component within revenue, linking sales to ongoing testing activity rather than only periodic instrument purchases. This model can support customer retention, steadier demand, and continued monetization of installed testing systems over multiple quarters.
Conservative Balance SheetLow leverage and a substantial equity cushion strengthen the company’s ability to absorb operating volatility without excessive financing pressure. This financial flexibility can support continued investment in diagnostic products and systems while reducing the balance-sheet risk associated with weaker cash generation.
Established Clinical Diagnostics FocusA focused position in in vitro diagnostics gives Eiken Chemical an established role in clinical testing and screening workflows. Products that support disease detection and laboratory analysis can remain strategically relevant as healthcare providers continue relying on routine diagnostic information.
Bears Say
Negative Free Cash FlowThe shift to negative free cash flow indicates that accounting profitability is no longer converting reliably into cash available for reinvestment or distribution. If sustained, weaker cash conversion could constrain capital allocation and make the business more exposed to working-capital needs or elevated investment.
Material Margin CompressionThe substantial decline in gross and operating margins shows that the company is operating below its earlier profitability profile. Persistent pressure from pricing, product mix, or costs would reduce earnings resilience and limit the cash generation available to fund innovation and commercial expansion.
Weak Revenue RecoveryA sharp revenue contraction followed by only modest recovery suggests limited top-line momentum over the recent period. Slower growth can reduce operating leverage, make margin recovery harder, and leave the company more dependent on efficiency improvements rather than expanding demand to rebuild earnings.
Eiken Chemical Co., Ltd. News
4549 FAQ
What was Eiken Chemical Co., Ltd.’s price range in the past 12 months?
Eiken Chemical Co., Ltd. lowest stock price was ¥2021.00 and its highest was ¥3500.00 in the past 12 months.
What is Eiken Chemical Co., Ltd.’s market cap?
Eiken Chemical Co., Ltd.’s market cap is ¥75.86B.
When is Eiken Chemical Co., Ltd.’s upcoming earnings report date?
Eiken Chemical Co., Ltd.’s upcoming earnings report date is Jan 29, 2027 which is in 90 days.
How were Eiken Chemical Co., Ltd.’s earnings last quarter?
Eiken Chemical Co., Ltd. released its earnings results on Oct 29, 2026. The company reported ¥20.58 earnings per share for the quarter.
Is Eiken Chemical Co., Ltd. overvalued?
According to Wall Street analysts Eiken Chemical Co., Ltd.’s price is currently Overvalued.
Does Eiken Chemical Co., Ltd. pay dividends?
Eiken Chemical Co., Ltd. pays a Semiannually dividend of ¥29 which represents an annual dividend yield of 2.52%. See more information on Eiken Chemical Co., Ltd. dividends here
What is Eiken Chemical Co., Ltd.’s EPS estimate?
Eiken Chemical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eiken Chemical Co., Ltd. have?
Eiken Chemical Co., Ltd. has 34,541,440 shares outstanding.
What happened to Eiken Chemical Co., Ltd.’s price movement after its last earnings report?
Eiken Chemical Co., Ltd. reported an EPS of ¥20.58 in its last earnings report. Following the earnings report the stock price went down -3.197%.
Which hedge fund is a major shareholder of Eiken Chemical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4549
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eiken Chemical Co., Ltd.
Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.
Technical Analysis
PHC Holdings Corp.
―
Techno Medica Co., Ltd.
―
Rion Co., Ltd.
―
Nihon Kohden Corporation
―